Deferoxamine (mesylate) (Standard)

Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate) . This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe (III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

Product Specifications

CAS Number

[138-14-7]

Product Name Alternative

Desferrioxamine B mesylate (Standard) ; DFOM (Standard)

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; Autophagy; HIF/HIF Prolyl-Hydroxylase; Reactive Oxygen Species (ROS) ; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/deferoxamine-mesylate-standard.html

Purity

99.47

Smiles

O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O

Molecular Formula

C26H52N6O11S

Molecular Weight

656.79

Precautions

H302, H315, H319, H335

References & Citations

[1]Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139 (3) :695e-706e.|[2]Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172 (3) :738-47.|[3]Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64.|[4]Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57 (3) :198-205.|[5]Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26 (11) :3255.